Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | PPIB | P23284 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800097 | 0.77 | METAP1 (0.54) | METAP1PPIBACHE | |
| SCHEMBL6802039 | 0.74 | CA12 (0.43) | BACE1METAP1PPIB | |
| SCHEMBL6800828 | 0.72 | PPARG (0.38) | — | |
| SCHEMBL6794626 | 0.71 | METAP1 (0.51) | METAP1PPIBACHE | |
| SCHEMBL6799540 | 0.70 | PPIB (0.58) | METAP1PPIBACHE | |
| SCHEMBL6795670 | 0.69 | CES2 (0.45) | METAP1PPIBACHE | |
| SCHEMBL6799152 | 0.67 | METAP1 (0.49) | METAP1PPIBACHE | |
| SCHEMBL6800106 | 0.65 | MAOA (0.47) | METAP1PPIB | |
| SCHEMBL6796531 | 0.64 | PPIB (0.55) | BACE1METAP1PPIBACHE | |
| SCHEMBL6795634 | 0.64 | SMN1; SMN2 (0.56) | METAP1PPIB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | MERCK & CO., INC. | 2004-04-29 | — | — | US | disclosed |
| EP-1339662-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS AND METHODS III | KARO BIO AB (SE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002046134-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS AND METHODS III | KARO BIO AB (SE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | ESRRA, ESRRB, FSHR | BACE1 1589/4885METAP1 4145/4885PPIB 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.